September 5, 2006 -- The FDA released a negative review of Genasense, the cancer drug from Genta, just before the Scientific Committee meets to assess the drug; GlaxoSmithKline and Adolor reported disappointing results from two trials of Entereg; Sepracor presented positive data from tests of its broncodilater; GlaxoSmithKline said the extended release version of Requip reduced the “off-time” of its Parkingson’s drug; Maxygen began a Phase I trial of a drug aimed at neutropenia; Neurocrine said the FDA will not require additional clinical trials for indiplon, its sleep medication; GTx reported the safety board recommended continuing two Phase III trials of a prostate cancer drug; Memory Pharma began dosing patients in a test of a bipolar disorder compound; Abbott said its drug eluting stent outperformed the Taxus stent; Connetics reported Pfizer began distributing a foam version of Rogaine; Oscient and Auxilium have dissolved their partnership to co-promote Testim testosterone gel; Warner Chilcott will offer 70.6 million shares to raise $1.217 billion in an IPO; and Rosetta Genomics will offer $36 million of stock in its IPO. The Centient Biotech 200™ rose 7 points to 3782.79, an increase of .20%. More details...
